Human papillomavirus and cervical cancer

被引:2449
作者
Crosbie, Emma J. [1 ]
Einstein, Mark H. [2 ,3 ]
Franceschi, Silvia [4 ]
Kitchener, Henry C. [1 ]
机构
[1] Univ Manchester, Inst Canc Sci, Manchester, Lancs, England
[2] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Albert Einstein Canc Ctr, Bronx, NY 10467 USA
[4] Int Agcy Res Canc, F-69372 Lyon, France
基金
美国国家卫生研究院; 比尔及梅琳达.盖茨基金会;
关键词
INTRAEPITHELIAL NEOPLASIA; HPV INFECTION; FOLLOW-UP; WOMEN; VACCINE; POPULATION; PERSISTENCE; CYTOLOGY; RISK; DNA;
D O I
10.1016/S0140-6736(13)60022-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cervical cancer is caused by human papillomavirus infection. Most human papillomavirus infection is harmless and clears spontaneously but persistent infection with high-risk human papillomavirus (especially type 16) can cause cancer of the cervix, vulva, vagina, anus, penis, and oropharynx. The virus exclusively infects epithelium and produces new viral particles only in fully mature epithelial cells. Human papillomavirus disrupts normal cell-cycle control, promoting uncontrolled cell division and the accumulation of genetic damage. Two effective prophylactic vaccines composed of human papillomavirus type 16 and 18, and human papillomavirus type 16, 18, 6, and 11 virus-like particles have been introduced in many developed countries as a primary prevention strategy. Human papillomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and as a test of cure after treatment. More sensitive than cytology, primary screening by human papillomavirus testing could enable screening intervals to be extended. If these prevention strategies can be implemented in developing countries, many thousands of lives could be saved.
引用
收藏
页码:889 / 899
页数:11
相关论文
共 104 条
  • [1] [Anonymous], BMJ
  • [2] Appleby P, 2007, LANCET, V370, P1609, DOI 10.1016/S0140-6736(07)61684-5
  • [3] The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy
    Arbyn, Marc
    Roelens, Jolien
    Cuschieri, Kate
    Cuzick, Jack
    Szarewski, Ann
    Ratnam, Sam
    Reuschenbach, Miriam
    Belinson, Suzanne
    Belinson, Jerome L.
    Monsonego, Joseph
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 132 (01) : 101 - 108
  • [4] Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
    Bernard, Hans-Ulrich
    Burk, Robert D.
    Chen, Zigui
    van Doorslaer, Koenraad
    zur Hausen, Harald
    de Villiers, Ethel-Michele
    [J]. VIROLOGY, 2010, 401 (01) : 70 - 79
  • [5] Boyer SN, 1996, CANCER RES, V56, P4620
  • [6] Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries
    Brisson, Marc
    Van de Velde, Nicolas
    Boily, Marie-Claude
    [J]. PUBLIC HEALTH GENOMICS, 2009, 12 (5-6) : 343 - 351
  • [7] The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
    Brown, Darron R.
    Kjaer, Susanne K.
    Sigurdsson, Kristjan
    Iversen, Ole-Erik
    Hernandez-Avila, Mauricio
    Wheeler, Cosette M.
    Perez, Gonzalo
    Koutsky, Laura A.
    Tay, Eng Hseon
    Garcia, Patricia
    Ault, Kevin A.
    Garland, Suzanne M.
    Leodolter, Sepp
    Olsson, Sven-Eric
    Tang, Grace W. K.
    Ferris, Daron G.
    Paavonen, Jorma
    Steben, Marc
    Bosch, F. Xavier
    Dillner, Joakim
    Joura, Elmar A.
    Kurman, Robert J.
    Majewski, Slawomir
    Munoz, Nubia
    Myers, Evan R.
    Villa, Luisa L.
    Taddeo, Frank J.
    Roberts, Christine
    Tadesse, Amha
    Bryan, Janine
    Lupinacci, Lisa C.
    Giacoletti, Katherine E. D.
    Sings, Heather L.
    James, Margaret
    Hesley, Teresa M.
    Barra, Eliav
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (07) : 926 - 935
  • [8] Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial
    Bulkmans, N. W. J.
    Berkhof, J.
    Rozendaal, L.
    van Kemenade, F. J.
    Boeke, A. J. P.
    Bulk, S.
    Voorhorst, F. J.
    Verheijen, R. H. M.
    Groningen, Kvan
    Boon, M. E.
    Ruitinga, W.
    van Ballegooijen, M.
    Snijders, P. J. F.
    Meijer, C. J. L. M.
    [J]. LANCET, 2007, 370 (9601) : 1764 - 1772
  • [9] Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches
    Campo, M. Saveria
    Roden, Richard B. S.
    [J]. JOURNAL OF VIROLOGY, 2010, 84 (03) : 1214 - 1220
  • [10] Carter JJ, 2001, CANCER RES, V61, P1934